Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tender Point Infiltration for Acute/Subacute Zoster Pain
NCT06344403Active, not recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of betamethasone and lidocaine in herpes zoster (HZ) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: The presence of postherpetic neuralgia using VAS score at 12 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
betamethasonelidocaine
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06344403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344403.